NovaBay Pharmaceuticals Inc (NBY)

[Minding]

NovaBay Pharmaceuticals Announces the Effectiveness of SEC Registration Statement

The rest of the explanation: Dilution.

Now we watch the P&L statement over the next 5 quarters.

Kind regards,
Minding

===============

EMERYVILLE, CA / ACCESSWIRE / April 21, 2015 / NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the registration statement on Form S-3 associated with the Company's March 2015 private placement has been declared effective by the U.S. Securities and Exchange Commission (SEC).

The registration of these shares causes them to be eligible for open trading in the stock market. The registration statement on Form S-3 and Notice of Effectiveness may be accessed through the SEC's website at http://www.sec.gov. Although the registration of these shares increases the number of shares available on the open market, it does not affect the daily operations of the Company.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics(R)

NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX(TM) Family of Products, including AVENOVA(TM) for the eye care market and NEUTROPHASE(R) for wound care, which was initially cleared by FDA, and CELLERX(TM) for the dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM). NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).